In vivo binding of the dopamine uptake inhibitor [18F]GBR 13119 in MPTP-treated C57BL/6 mice

Int J Rad Appl Instrum B. 1991;18(7):803-6. doi: 10.1016/0883-2897(91)90021-c.

Abstract

The in vivo regional distribution of [18F]GBR 13119 (1-[(4-[18F]fluorophenyl(phenyl)methoxy)ethyl]-4-(3-phenylpropyl) piperazine), a specific dopamine reuptake inhibitor, was examined in brains of C57BL/6 mice after MPTP treatment. At 2 weeks post MPTP the in vivo specific binding of [18F]GBR 13119 in striatum was decreased 63% relative to age and sex-matched controls. Animals studied at 6 and 8 weeks after MPTP treatment showed a gradual recovery of specific [18F]GBR 13119 binding in the striatum. No significant changes were observed in binding of radiotracer to cerebellum or cortex after MPTP treatment, nor were age-related changes observed in control mice. In vivo radiotracer studies thus appear useful for following gradual changes in the dopamine uptake system of mouse brain after neurotoxin treatment.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
  • Animals
  • Brain / metabolism
  • Dopamine / metabolism*
  • Fluorine Radioisotopes*
  • Ligands
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Piperazines / metabolism*

Substances

  • Fluorine Radioisotopes
  • Ligands
  • Piperazines
  • GBR 13119
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Dopamine